NO20020090L - Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midler - Google Patents
Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midlerInfo
- Publication number
- NO20020090L NO20020090L NO20020090A NO20020090A NO20020090L NO 20020090 L NO20020090 L NO 20020090L NO 20020090 A NO20020090 A NO 20020090A NO 20020090 A NO20020090 A NO 20020090A NO 20020090 L NO20020090 L NO 20020090L
- Authority
- NO
- Norway
- Prior art keywords
- homocysteine
- pharmaceutical
- fatty acids
- formulations containing
- essential fatty
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9916536.7A GB9916536D0 (en) | 1999-07-14 | 1999-07-14 | Nutritional or pharmaceutical compositions |
PCT/GB2000/002681 WO2001003696A1 (en) | 1999-07-14 | 2000-07-11 | Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20020090L true NO20020090L (no) | 2002-01-08 |
NO20020090D0 NO20020090D0 (no) | 2002-01-08 |
Family
ID=10857244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020090A NO20020090D0 (no) | 1999-07-14 | 2002-01-08 | Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midler |
Country Status (24)
Country | Link |
---|---|
US (1) | US20050147665A1 (no) |
EP (1) | EP1200085A1 (no) |
JP (1) | JP2003504333A (no) |
KR (1) | KR20020025088A (no) |
CN (1) | CN1223346C (no) |
AU (1) | AU6167800A (no) |
BR (1) | BR0013157A (no) |
CA (1) | CA2377502A1 (no) |
CZ (1) | CZ200258A3 (no) |
EE (1) | EE200200021A (no) |
GB (1) | GB9916536D0 (no) |
HK (1) | HK1042853A1 (no) |
HU (1) | HUP0202342A3 (no) |
IL (1) | IL147556A0 (no) |
IS (1) | IS6205A (no) |
MX (1) | MXPA01013210A (no) |
NO (1) | NO20020090D0 (no) |
NZ (1) | NZ516101A (no) |
PL (1) | PL352185A1 (no) |
RU (1) | RU2001134300A (no) |
SK (1) | SK332002A3 (no) |
TR (1) | TR200200045T2 (no) |
WO (1) | WO2001003696A1 (no) |
ZA (1) | ZA200200259B (no) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
KR20020069539A (ko) * | 2001-02-26 | 2002-09-05 | 주식회사 두산 | 뇌세포 보호용 조성물 |
KR100427637B1 (ko) * | 2001-06-05 | 2004-04-27 | 이인규 | 세포내 에너지 소비 증가제 |
JPWO2002102364A1 (ja) * | 2001-06-18 | 2004-09-30 | 山田 幸子 | PPARγ作動性医薬組成物 |
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
ATE341334T1 (de) * | 2002-06-20 | 2006-10-15 | Astion Dermatology As | Neue komplexe von polyhydroxyalkanfettsäureestern und niacinamid |
JP4611622B2 (ja) * | 2002-07-11 | 2011-01-12 | 第一三共株式会社 | 血中脂質改善又は血中ホモシステイン低下のための医薬組成物 |
WO2004006919A1 (ja) * | 2002-07-11 | 2004-01-22 | Sankyo Company, Limited | 血中脂質改善又は血中ホモシステイン低下のための医薬組成物 |
US20040132819A1 (en) * | 2002-08-06 | 2004-07-08 | Nancy Auestad | Appetite control method |
CA2499501A1 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
KR20040063616A (ko) * | 2003-01-08 | 2004-07-14 | 김원호 | 다이어트 식품용 조제 |
JP2005082523A (ja) * | 2003-09-08 | 2005-03-31 | Toru Hasegawa | 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬 |
JP4522075B2 (ja) * | 2003-10-29 | 2010-08-11 | サントリーホールディングス株式会社 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
ITMI20040069A1 (it) | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
US9452150B2 (en) * | 2004-08-18 | 2016-09-27 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
WO2006054757A1 (ja) * | 2004-11-16 | 2006-05-26 | Astellas Pharma Inc. | カスパーゼ阻害剤 |
WO2006099237A1 (en) * | 2005-03-10 | 2006-09-21 | Sciele Pharma, Inc. | Nutritional preparations |
US20060217385A1 (en) * | 2005-03-10 | 2006-09-28 | Edwards John B | Nutritional preparations |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
US20070004639A1 (en) * | 2005-07-01 | 2007-01-04 | Bodybio, Inc. | Methods and compositions for treating Parkinson's disease |
EP1921928A1 (en) | 2005-08-26 | 2008-05-21 | Nestec S.A. | Nutrition for obese patients |
JP5113527B2 (ja) * | 2005-11-11 | 2013-01-09 | 持田製薬株式会社 | ゼリー組成物 |
US8367121B2 (en) * | 2005-11-23 | 2013-02-05 | Florida A & M University | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease |
JP5176127B2 (ja) * | 2006-01-11 | 2013-04-03 | 大正製薬株式会社 | 視覚機能障害の予防または改善剤 |
US20090311329A1 (en) * | 2006-04-20 | 2009-12-17 | Technion Research And Development Foundation Ltd | Casein micelles for nanoencapsulation of hydrophobic compounds |
JP5300186B2 (ja) * | 2006-08-23 | 2013-09-25 | 株式会社明治 | 血中ホモシステイン濃度の上昇を抑制する妊婦用の乳由来組成物 |
KR100832675B1 (ko) * | 2006-09-22 | 2008-05-26 | 한상왕 | 영양 보조제 |
KR101578498B1 (ko) | 2006-12-28 | 2015-12-18 | 산토리 홀딩스 가부시키가이샤 | 신경 재생제 |
US8343541B2 (en) * | 2007-03-15 | 2013-01-01 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
WO2008153220A1 (ja) * | 2007-06-13 | 2008-12-18 | Suntory Holdings Limited | 血管疾患の予防又は治療剤 |
EP2689782B1 (en) * | 2007-06-26 | 2020-05-13 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
WO2009002148A1 (en) * | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
CA2703645C (en) | 2007-10-25 | 2015-01-27 | Nutri Co., Ltd. | Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
EP2229939A4 (en) * | 2008-01-10 | 2011-04-27 | Takeda Pharmaceutical | CAPSULE FORMULATION |
EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
US8865733B2 (en) * | 2008-11-06 | 2014-10-21 | Altman Enterprises, LLC | Medication and treatment for disease |
NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
NZ789295A (en) | 2009-04-29 | 2024-02-23 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
CN114053258A (zh) | 2009-06-15 | 2022-02-18 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
CA3162668A1 (en) * | 2010-02-12 | 2011-08-18 | Gentelon, Inc. | Compositions and methods for treating depression |
NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US9216209B1 (en) | 2011-06-06 | 2015-12-22 | Kilmer S. McCully | Compositions and method for utilization of thioretinamide in therapy of degenerative diseases of aging |
US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
AU2013235266B2 (en) | 2012-03-20 | 2017-10-19 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
JP2015522029A (ja) | 2012-06-29 | 2015-08-03 | アマリン ファーマシューティカルス アイルランド リミテッド | スタチン療法中の患者における心血管系イベントの危険性を減少させる方法 |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
CN103432156A (zh) * | 2013-08-30 | 2013-12-11 | 深圳奥萨医药有限公司 | ω-3脂肪酸和B族维生素的药物组合物及其用途 |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
GB201405033D0 (en) * | 2014-03-20 | 2014-05-07 | Isis Innovation | Combination therapy |
US9655910B2 (en) | 2014-03-21 | 2017-05-23 | Bodybio Inc. | Compositions and methods for treating addiction |
US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
CA2953633A1 (en) | 2014-06-04 | 2015-12-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and use of same |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
US10631564B2 (en) | 2015-06-19 | 2020-04-28 | University Of Southern California | Enterically coated microparticle compositions and methods for modified nutrient delivery |
WO2017091279A1 (en) * | 2015-11-23 | 2017-06-01 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018144088A1 (en) | 2016-11-03 | 2018-08-09 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
CN112218630A (zh) | 2018-09-24 | 2021-01-12 | 阿马里纳药物爱尔兰有限公司 | 降低受试者的心血管事件的风险的方法 |
US11779910B2 (en) | 2020-02-21 | 2023-10-10 | Biojiva Llc | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237118A (en) * | 1972-03-06 | 1980-12-02 | Howard Alan N | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
GB8719988D0 (en) * | 1987-08-25 | 1987-09-30 | Efamol Ltd | Chemical compounds |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
GB9715203D0 (en) * | 1997-07-19 | 1997-09-24 | Piper Edwina M | Composition |
-
1999
- 1999-07-14 GB GBGB9916536.7A patent/GB9916536D0/en not_active Ceased
-
2000
- 2000-07-11 WO PCT/GB2000/002681 patent/WO2001003696A1/en not_active Application Discontinuation
- 2000-07-11 KR KR1020017016625A patent/KR20020025088A/ko not_active Application Discontinuation
- 2000-07-11 BR BR0013157-1A patent/BR0013157A/pt not_active IP Right Cessation
- 2000-07-11 SK SK33-2002A patent/SK332002A3/sk unknown
- 2000-07-11 CN CNB008103399A patent/CN1223346C/zh not_active Expired - Fee Related
- 2000-07-11 CA CA002377502A patent/CA2377502A1/en not_active Abandoned
- 2000-07-11 EE EEP200200021A patent/EE200200021A/xx unknown
- 2000-07-11 IL IL14755600A patent/IL147556A0/xx unknown
- 2000-07-11 NZ NZ516101A patent/NZ516101A/xx unknown
- 2000-07-11 CZ CZ200258A patent/CZ200258A3/cs unknown
- 2000-07-11 MX MXPA01013210A patent/MXPA01013210A/es unknown
- 2000-07-11 AU AU61678/00A patent/AU6167800A/en not_active Abandoned
- 2000-07-11 TR TR2002/00045T patent/TR200200045T2/xx unknown
- 2000-07-11 PL PL00352185A patent/PL352185A1/xx not_active Application Discontinuation
- 2000-07-11 HU HU0202342A patent/HUP0202342A3/hu unknown
- 2000-07-11 JP JP2001508976A patent/JP2003504333A/ja active Pending
- 2000-07-11 EP EP00948105A patent/EP1200085A1/en not_active Withdrawn
- 2000-07-11 RU RU2001134300/14A patent/RU2001134300A/ru not_active Application Discontinuation
-
2001
- 2001-12-18 IS IS6205A patent/IS6205A/is unknown
-
2002
- 2002-01-08 NO NO20020090A patent/NO20020090D0/no unknown
- 2002-01-11 ZA ZA200200259A patent/ZA200200259B/xx unknown
- 2002-06-24 HK HK02104664.5A patent/HK1042853A1/zh unknown
-
2004
- 2004-11-24 US US10/995,533 patent/US20050147665A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA200200259B (en) | 2002-12-24 |
RU2001134300A (ru) | 2003-08-27 |
CN1361690A (zh) | 2002-07-31 |
AU6167800A (en) | 2001-01-30 |
CA2377502A1 (en) | 2001-01-18 |
HUP0202342A3 (en) | 2003-02-28 |
HUP0202342A2 (hu) | 2002-11-28 |
WO2001003696A1 (en) | 2001-01-18 |
NO20020090D0 (no) | 2002-01-08 |
CZ200258A3 (cs) | 2002-06-12 |
HK1042853A1 (zh) | 2002-08-30 |
JP2003504333A (ja) | 2003-02-04 |
SK332002A3 (en) | 2002-12-03 |
PL352185A1 (en) | 2003-08-11 |
TR200200045T2 (tr) | 2002-05-21 |
US20050147665A1 (en) | 2005-07-07 |
NZ516101A (en) | 2003-06-30 |
IL147556A0 (en) | 2002-08-14 |
KR20020025088A (ko) | 2002-04-03 |
CN1223346C (zh) | 2005-10-19 |
MXPA01013210A (es) | 2004-06-03 |
BR0013157A (pt) | 2002-04-02 |
EE200200021A (et) | 2003-04-15 |
EP1200085A1 (en) | 2002-05-02 |
IS6205A (is) | 2001-12-18 |
GB9916536D0 (en) | 1999-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20020090D0 (no) | Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midler | |
NO973283D0 (no) | Konjugater mellom terapeutiske forbindelser og fettsyrer | |
ID24654A (id) | Formulasi farmasi omeprazola | |
NO992339L (no) | Farmasöytiske formuleringer | |
NO20020086L (no) | Smaksmaskerte farmasöytiske flytende formuleringer | |
NO20021401D0 (no) | Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser | |
EE05067B1 (et) | Aminoproplfosfiinhapped ning nende kasutamine meditsiinis | |
FI950910A (fi) | Rasvahappojohdannaiset | |
DK1001813T3 (da) | Farmaceutiske formuleringer indeholdende voriconazol | |
ID22565A (id) | Penggunaan nanodispersi dalam formulasi akhir obat | |
HUP0201444A3 (en) | Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants | |
DK1183026T3 (da) | Forbedrede farmaceutiske formuleringer omfattende ritonavir | |
IS2841B (is) | Samstæða hluta og lyfjasamsetningar | |
NO20004399D0 (no) | Koleinsyreamider og farmasøytiske sammensetninger | |
DE60018967D1 (de) | Inierzierbare valnemulin formulierung | |
HUP0303694A3 (en) | Aza-amino acid derivatives and pharmaceutical | |
ID30032A (id) | Formulasi farmasi | |
ITMI941169A0 (it) | Formulazioni farmaceutiche | |
HUP0500956A3 (en) | Oxapenem-3-carboxylic acids and pharmaceutical compositions containing them | |
IL144706A0 (en) | Ether type lipid a-1 carboxylic acid analogue and pharmaceutical compositions containing the same | |
HUP0102705A3 (en) | Alpha-amino acid phenyl ester derivatives and their use and pharmaceutical compositions comprising them | |
NO306491B1 (no) | Oppdrettsmaer og anvendelse derav | |
SE9803619D0 (sv) | Fatty acid formulation | |
SE9803952D0 (sv) | Pharmaceutical formulation | |
IT1313134B1 (it) | Dispositivo gonfiabile per l'esposizione di messaggi pubblicitari |